Oncolytic virus-initiated protective immunity against prostate cancer.
Recently reovirus-based oncotherapy has been successfully implemented for the treatment of prostate cancer. In this report, we show that apart from its primary direct cancer-killing activity, reovirus oncotherapy overrides tumor-associated immune evasion strategies and confers protective antiprostate cancer immunity. Prostate cancer represents an ideal target for immunotherapies. However, currently available immune interventions fail to induce clinically significant antiprostate cancer immune responses, owing to the immunosuppressive microenvironment associated with this disease. We show here that during the process of oncolysis, reovirus acts upon prostate cancer cells and initiates proinflammatory cytokines and major histocompatibility complex (MHC) class I molecule expression. In an immunocompetent transgenic adenocarcinoma of mouse prostate (TRAMP) model, reovirus oncotherapy induces the homing of CD8(+) T and NK cells in tumors and the display of tumor-associated antigens (TAAs) on antigen-presenting cells (APCs), and endows dendritic cells (DCs) with a capacity to successfully present TAAs to tumor-specific CD8(+) T cells. These newly generated immunological events lead to the development of strong antiprostate cancer T cell responses, which restrict the growth of subsequently, implanted syngeneic tumor in an antigen-specific, but reovirus-independent manner. Such reovirus-initiated antiprostate cancer immunity represents a clinically valuable entity that can promote long-term cancer-free health even after discontinuation of the primary oncotherapy.
Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
Shashi A
SA
Gujar
D A
DA
Pan
Paola
P
Marcato
Katy A
KA
Garant
Patrick W K
PW
Lee
D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000276:immunology; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D050504:Oncolytic Viruses / Q000235:genetics / Q000276:immunology* / Q000502:physiology*; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000628:therapy*
Oncogene. 2005 Nov 21;24(52):7720-8
16299532
Semin Oncol. 2003 Oct;30(5):649-58
14571412
J Immunol Methods. 2003 Oct 1;281(1-2):65-78
14580882
J Immunol. 2008 May 1;180(9):6018-26
18424722
Nat Rev Immunol. 2010 Aug;10(8):580-93
20651745
Cancer Res. 2007 Mar 15;67(6):2840-8
17363607
Lancet Oncol. 2008 Jul;9(7):610-2
18598928
Mol Cancer Ther. 2010 Nov;9(11):2924-33
20978162
Rev Med Virol. 2007 Jan-Feb;17(1):35-43
17146842
Cell Cycle. 2005 Apr;4(4):556-9
15753655
Eur J Cancer. 1994;30A(12):1797-803
7880609
Cancer Res. 2002 Aug 1;62(15):4427-33
12154050
Mol Ther. 2007 Aug;15(8):1522-30
17457318
J Natl Cancer Inst. 1995 Feb 15;87(4):280-5
7707419
N Engl J Med. 2005 Sep 22;353(12):1224-35
16177248
Br J Cancer. 2006 Aug 21;95(4):425-30
16880794
Cancer Res. 1997 Aug 15;57(16):3325-30
9269988
Immunol Lett. 2005 Jan 15;96(1):3-9
15585302
Curr Opin Mol Ther. 2009 Oct;11(5):532-9
19806501
Cell. 1994 Jan 14;76(1):17-27
8287475
Vaccine. 2011 Apr 12;29(17):3341-55
20713100
Prostate. 2009 Nov 1;69(15):1694-703
19670224
Curr Opin Urol. 2010 May;20(3):241-6
20179598
Curr Opin Urol. 2008 May;18(3):261-2
18382234
Cancer Gene Ther. 2010 Jan;17(1):69-70
19590528
J Clin Oncol. 2009 Sep 1;27(25):4035-7
19635998
Immunol Invest. 2005;34(2):215-36
15921160
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):91-8
20223697
Prostate Cancer Prostatic Dis. 2008;11(4):334-41
17938645
Clin Cancer Res. 2008 Jun 1;14(11):3254-61
18519750
Eur Urol. 2008 Apr;53(4):694-708
18061335
Expert Opin Biol Ther. 2009 Jul;9(7):817-30
19527106
Rev Urol. 2007;9 Suppl 1:S29-38
17387370
J Clin Oncol. 2009 Sep 1;27(25):4047-54
19636017
Curr Urol Rep. 2010 May;11(3):202-7
20425628
Clin Cancer Res. 2009 Jul 1;15(13):4374-4381
19509134
Immunity. 1997 Jun;6(6):715-26
9208844
Int Immunol. 1994 Mar;6(3):369-76
8186188
Oncologist. 2009 Apr;14(4):391-8
19342474
Cancer Immunol Immunother. 2004 Jun;53(6):560-6
14985861
Science. 1998 Nov 13;282(5392):1332-4
9812900
J Immunol. 2010 Jun 15;184(12):6658-69
20483744
Cancer Res. 2010 Mar 15;70(6):2435-44
20215509
J Immunol. 2007 Dec 1;179(11):7244-53
18025166
Annu Rev Immunol. 2007;25:267-96
17134371
J Virol. 2009 Apr;83(8):3861-76
19193791